
AxoGen (AXGN) Stock Forecast & Price Target
AxoGen (AXGN) Analyst Ratings
Bulls say
Axogen Inc. demonstrated strong momentum in its business with a year-over-year revenue growth of 23.5% and an increase in active breast resensation programs by 7%, contributing to a significant rise in productivity among high-potential accounts. The company raised its full-year 2025 guidance to at least 19% growth, reflecting a solid outlook bolstered by improvements in insurance coverage for its products, which expanded to over 64% of covered lives. Additionally, industry recognition of nerve allograft as a standard medical practice by professional associations further supports Axogen's market position and growth potential.
Bears say
Axogen Inc's reliance on its flagship product, Avance Nerve Graft, is expected to decline due to the launch of newer products, Axoguard HA+ and Avive+, though uncertainties surrounding the FDA submission pose potential risks to revenue growth. The company's revenue generation from high potential accounts has decreased, which is projected to weigh on overall account growth and market penetration, highlighting vulnerabilities in Axogen's growth strategy. Despite reporting a gross margin of 76.6% surpassing expectations, significant one-time costs related to the anticipated BLA approval and potential label restrictions may further hinder profitability and investor confidence in the firm.
This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.
AxoGen (AXGN) Analyst Forecast & Price Prediction
Start investing in AxoGen (AXGN)
Order type
Buy in
Order amount
Est. shares
0 shares